EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Thyroid hormone levels in children with Prader–Willi syndrome: a randomized controlled growth hormone trial and 10-year growth hormone study

Demi J Trueba-Timmermans iD, Lionne N Grootjen, Gerthe F Kerkhof, Edmond H H M Rings, Anita C S Hokken-Koelega iD

European Journal of Endocrinology · 2024

DOI: 10.1093/ejendo/lvae088 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift European Journal of Endocrinology, 2024. Verfasst von Demi J Trueba-Timmermans und 4 weiteren Autor:innen. Beteiligte Einrichtung: Dutch Reference Center for Prader-Willi Syndrome, 3015 CN Rotterdam, The Netherlands. Hauptthemen laut MEDLINE: Prader-Willi Syndrome, Human Growth Hormone. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Pfizer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

Several endocrine abnormalities were reported in children with Prader–Willi syndrome (PWS), including hypothyroidism. Growth hormone (GH) treatment may impact the thyroid hormone axis by direct inhibition of T4 or TSH secretion or by increased peripheral conversion of free T4 (FT4) to T3.

Objective

The objective of this study is to evaluate thyroid function during GH treatment in a large group of children with PWS.

Methods

Serum FT4, T3, and TSH are measured in a 2-year randomized controlled GH trial (RCT) and 10-year longitudinal GH study (GH treatment with 1.0 mg/m²/day [∼0.035 mg/kg/day]).

Results

Forty-nine children with PWS were included in the 2-year RCT (median [interquartile range, IQR] age: GH group 7.44 [5.47-11.80] years, control group 6.04 [4.56-7.39] years). During the first 6 months, median (IQR) FT4 standard deviation score (SDS) decreased in the GH group from −0.84 (−1.07 to −0.62) to −1.32 (−1.57 to −1.08) (P < .001) and T3 SDS increased from 0.31 (−0.01-0.63) to 0.56 (0.32-0.79) (P = .08), while in the control group, FT4 and T3 SDS remained unchanged. In our 10-year GH study, 240 children with PWS (median [IQR] age: 1.27 (0.54-4.17) years] were included. Between 2 and 10 years, median (IQR) FT4 SDS remained unchanged, being −0.87 (−0.98 to −0.77) after 2 years and −0.88 (−1.03 to −0.74) after 10 years (P = .13). TSH SDS decreased from −0.35 (−0.50 to −0.21) after 2 years to −0.68 (−0.84 to −0.53) after 10 years (P < .001).

Conclusions

Our findings suggest that GH treatment decreases FT4 levels, due to increased peripheral conversion of FT4 to T3 in the first months of treatment, but thereafter, FT4 and T3 normalize and remain stable during long-term GH treatment in almost all children and adolescents with PWS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prader-Willi SyndromeHuman Growth HormoneHumansChildMaleFemaleChild, PreschoolLongitudinal StudiesTriiodothyronineThyroxineThyroid HormonesThyrotropin

Stichwörter der Autor:innen

Prader–Willi syndromechildrengrowth hormonethyroid function

Substanzen

Human Growth HormoneTriiodothyronineThyroxineThyroid HormonesThyrotropin

Autor:innen und Institutionen

  • Dutch Reference Center for Prader-Willi Syndrome, 3015 CN Rotterdam, The Netherlands.
  • Dutch Growth Research Foundation, 3016 AH Rotterdam, The Netherlands.
  • Department of Pediatrics, Subdivision of Endocrinology, Erasmus University Medical Center-Sophia Children's Hospital, 3015 CN Rotterdam, The Netherlands.
  • Department of Pediatrics, Erasmus University Medical Center-Sophia Children's Hospital, 3015 CN Rotterdam, The Netherlands.

ORCID-Profile: Demi J Trueba-Timmermans, Anita C S Hokken-Koelega

Förderung

  • Pfizer

Zitieren

APA

Trueba-Timmermans, D. J., Grootjen, L. N., Kerkhof, G. F., Rings, E. H. H. M., & Hokken-Koelega, A. C. S. (2024). Thyroid hormone levels in children with Prader–Willi syndrome: a randomized controlled growth hormone trial and 10-year growth hormone study. European Journal of Endocrinology. https://doi.org/10.1093/ejendo/lvae088

Vancouver

Trueba-Timmermans DJ, Grootjen LN, Kerkhof GF, Rings EHHM, Hokken-Koelega ACS. Thyroid hormone levels in children with Prader–Willi syndrome: a randomized controlled growth hormone trial and 10-year growth hormone study. European Journal of Endocrinology. 2024. doi:10.1093/ejendo/lvae088

BibTeX
@article{TruebaTimmermans2024,
  author = {Trueba-Timmermans, Demi J and Grootjen, Lionne N and Kerkhof, Gerthe F and Rings, Edmond H H M and Hokken-Koelega, Anita C S},
  title = {Thyroid hormone levels in children with Prader–Willi syndrome: a randomized controlled growth hormone trial and 10-year growth hormone study},
  journal = {European Journal of Endocrinology},
  year = {2024},
  doi = {10.1093/ejendo/lvae088}
}
Kostenlos starten →